
3卷 第6期
Latest Research in Treatment of CJD
Latest Research in Treatment of CJD
- 2022年3卷第6期 页码:75-77
纸质出版日期: 2022-06-25
DOI:10.47297/taposatWSP2633-456912.20220306
Scan QR Code
3卷 第6期
Fuzhou Pingdong Senior High School, Fuzhou Fujian 350003, P.R.China
纸质出版日期: 2022-06-25 ,
Scan QR Code
(2022). Latest Research in Treatment of CJD. 科技理论与实践(英文版), 3(6), 75-77.
Lan Liang.Latest Research in Treatment of CJD[J].Theory and Practice of Science and Technology,2022,03(06):75-77.
(2022). Latest Research in Treatment of CJD. 科技理论与实践(英文版), 3(6), 75-77. DOI: 10.47297/taposatWSP2633-456912.20220306.
Lan Liang.Latest Research in Treatment of CJD[J].Theory and Practice of Science and Technology,2022,03(06):75-77. DOI: 10.47297/taposatWSP2633-456912.20220306.
Creutzfeldt-jakob disease(CJD) is a degenerative encephalopathy caused by prions. It has a long incubation period
a 100% fatality rate
and can be transmitted by infection and heredity. At present
there is no treatment method that can eradicate the etiology of this disease
and patients mainly receive symptomatic treatment to improve symptoms. This paper aims to review some current treatment strategies
drug tests
and then put forward suggestions for future research directions.
Prion proteinTreatment and preventionDrug test
Sikorska, B., & Liberski, P. P. (2012). Human prion diseases: from Kuru to variant Creutzfeldt-Jakob disease. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease, 457-496.
Pan, Keh-Ming. (1993). Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Sciences, 90(23): 10962-10966.
Dobson, C.M. (2001). The structural basis of protein folding and its links with human disease. Philosophical Transactions of the Royal Society of London (Biological Sciences), 356 (1406): 133-45.
Mead, Simon. (2022). Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme. The Lancet Neurology, 21(4): 342-354.
Qin, K., O'Donnell, M., & Zhao, R. Y. (2006). Doppel: more rival than double to prion. Neuroscience, 141(1), 1-8.
Skillbäck, T., Rosén, C., Asztely, F., et al. (2014). Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. JAMA neurology, 71(4): 476-483.
Mizrahi, M., Friedman-Levi, Y., Larush, L., et al. (2014). Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. Nanomedicine: Nanotechnology, Biology and Medicine, 10(6): 1353-1363.
Uttara, B., Singh, A. V., Zamboni, P., et al. (2009). Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Current neuropharmacology, 7(1): 65-74.
Haider, L., Fischer, M. T., Frischer, J. M., et al. (2011). Oxidative damage in multiple sclerosis lesions. Brain, 134(7): 1914-1924.
Freixes, M., Rodriguez, A., Dalfo, E., et al. (2006). Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt–Jakob disease. Neurobiology of Aging, 27(12): 1807-1815.
Lu, D., Giles, K., Li, Z., et al. (2013). Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. Journal of Pharmacology and Experimental Therapeutics, 347(2), 325-338.
Related Articles
Related Author
Related Institution